Filtered By:
Condition: Heart Attack
Drug: Enalapril

This page shows you your search results in order of date.

Order by Relevance | Date

Total 18 results found since Jan 2013.

Comparing Cardiovascular Outcomes and Costs of Perindopril-, Enalapril- or Losartan-Based Antihypertensive Regimens in South Africa: Real-World Medical Claims Database Analysis
CONCLUSION: In South African individuals with private health insurance, a perindopril-based antihypertensive regimen provided better clinical and cost outcomes compared with other regimens.PMID:37730949 | DOI:10.1007/s12325-023-02641-8
Source: Adv Data - September 21, 2023 Category: Epidemiology Authors: Jacques R Snyman Freedom Gumedze Erika S W Jones Olufunke A Alaba Nqoba Tsabedze Alykhan Vira Ntobeko A B Ntusi Source Type: research

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease
CONCLUSIONS: There is currently insufficient evidence to determine the effectiveness of ACEi or ARB in patients with stage 1 to 3 CKD who do not have DM. The available evidence is overall of very low certainty and high risk of bias. We have identified an area of large uncertainty for a group of patients who account for most of those diagnosed as having CKD.PMID:37466151 | DOI:10.1002/14651858.CD007751.pub3
Source: Cochrane Database of Systematic Reviews - July 19, 2023 Category: General Medicine Authors: Tess E Cooper Claris Teng David J Tunnicliffe Brydee A Cashmore Giovanni Fm Strippoli Source Type: research

Cost-effectiveness of folic acid therapy for primary prevention of stroke in patients with hypertension
For hypertensive patients without a history of stroke or myocardial infarction (MI), the China Stroke Primary Prevention Trial (CSPPT) demonstrated that treatment with enalapril-folic acid reduced the risk of ...
Source: BMC Medicine - October 25, 2022 Category: Internal Medicine Authors: Tiantian Zhang, Zhuoru Liang, Tengfei Lin, David J. Cohen, Alejandro Arrieta, Xiaobin Wang, Xianhui Qin, Binyan Wang, Yong Huo, Gordon G. Liu, Jie Jiang and Zugui Zhang Tags: Research article Source Type: research

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Publication date: 24–30 August 2019Source: The Lancet, Volume 394, Issue 10199Author(s): Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi, Karla Hemming, Farin Kamangar, Abdolsamad Gharavi, Mohammad Reza Ostovaneh, Alireza Nateghi, Masoud Majed, Behrooz Navabakhsh, Shahin Merat, Akram Pourshams, Mahdi Nalini, Fatemeh Malekzadeh, Masoumeh Sadeghi, Noushin Mohammadifard, Nizal Sarrafzadegan, Mohammad Naemi-Tabiei, Abdolreza Fazel, Paul BrennanSummaryBackgroundA fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income ...
Source: The Lancet - August 23, 2019 Category: General Medicine Source Type: research

Homocysteine-lowering interventions for preventing cardiovascular events.
CONCLUSIONS: In this third update of the Cochrane review, there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination comparing with placebo on myocardial infarction, death from any cause or adverse events. In terms of stroke, this review found a small difference in effect favouring to homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination comparing with placebo.There were uncertain effects of enalapril plus folic acid compared with enalapril on stroke; approxima...
Source: Cochrane Database of Systematic Reviews - August 17, 2017 Category: General Medicine Authors: Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M Tags: Cochrane Database Syst Rev Source Type: research

The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF
Conclusions Compared with enalapril, sacubitril/valsartan reduced the risk of both the primary endpoint and a coronary composite outcome in PARADIGM-HF. Additional studies on the effect of sacubitril/valsartan on atherothrombotic outcomes in high risk patients are merited.
Source: American Heart Journal - March 14, 2017 Category: Cardiology Source Type: research

Longitudinal association between fasting blood glucose concentrations and first stroke in hypertensive adults in China: effect of folic acid intervention Cardiovascular disease risk
Conclusions: In Chinese hypertensive adults, an FBG concentration ≥7.0 mmol/L or diabetes is associated with an increased risk of first stroke; this increased risk is reduced by 34% with folic acid treatment. These findings warrant additional investigation. This trial was registered at clinicaltrials.gov as NCT00794885.
Source: American Journal of Clinical Nutrition - February 28, 2017 Category: Nutrition Authors: Xu, R. B., Kong, X., Xu, B. P., Song, Y., Ji, M., Zhao, M., Huang, X., Li, P., Cheng, X., Chen, F., Zhang, Y., Tang, G., Qin, X., Wang, B., Hou, F. F., Dong, Q., Chen, Y., Yang, T., Sun, N., Li, X., Zhao, L., Ge, J., Ji, L., Huo, Y., Li, J. Tags: Cardiovascular disease risk Source Type: research

Longitudinal association between fasting blood glucose concentrations and first stroke in hypertensive adults in China: effect of folic acid intervention.
CONCLUSIONS: In Chinese hypertensive adults, an FBG concentration ≥7.0 mmol/L or diabetes is associated with an increased risk of first stroke; this increased risk is reduced by 34% with folic acid treatment. These findings warrant additional investigation. This trial was registered at clinicaltrials.gov as NCT00794885. PMID: 28122783 [PubMed - as supplied by publisher]
Source: The American Journal of Clinical Nutrition - January 24, 2017 Category: Nutrition Authors: Xu RB, Kong X, Xu BP, Song Y, Ji M, Zhao M, Huang X, Li P, Cheng X, Chen F, Zhang Y, Tang G, Qin X, Wang B, Hou FF, Dong Q, Chen Y, Yang T, Sun N, Li X, Zhao L, Ge J, Ji L, Huo Y, Li J Tags: Am J Clin Nutr Source Type: research

Effect of folic acid supplementation on cancer risk among adults with hypertension in China: A randomized clinical trial
This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - March 17, 2016 Category: Cancer & Oncology Authors: Xianhui Qin, Lin Shen, Rong Zhang, Youbao Li, Xiaobin Wang, Binyan Wang, Xiaodong Jiang, Hua Jiang, Yu Lei, Fan Fan Hou, Jin Gu, Yong Huo Tags: Research Article Source Type: research

Haemodynamic Responses to Selective Vagal Nerve Stimulation under Enalapril Medication in Rats
by Mortimer Gierthmuehlen, Thomas Stieglitz, Josef Zentner, Dennis T. T. Plachta Selective vagal nerve stimulation (sVNS) has been demonstrated to lower blood pressure (BP) in rats without causing major side effects. This method might be adapted for the treatment of therapy-resistant hypertension in patients. Converting enzyme inhibitors (CEIs) are among the first drugs that are administered for arterial hypertension and prominently reduce BP primarily by interacting with the renin-angiotensin system of the kidneys. Beyond the reduction of BP, CEI have a positive effect on the survival rate after myocardial infarction; th...
Source: PLoS One - January 14, 2016 Category: Biomedical Science Authors: Mortimer Gierthmuehlen et al. Source Type: research

Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial
Conclusion The infrastructure of GCS and the primary health care system in Iran enabled the conduct of this pragmatic large-scale trial. If the polypill strategy proves effective, it may be implemented to prevent cardiovascular disease in developing countries.
Source: European Journal of Preventive Cardiology - November 9, 2015 Category: Cardiology Authors: Ostovaneh, M. R., Poustchi, H., Hemming, K., Marjani, H., Pourshams, A., Nateghi, A., Majed, M., Navabakhsh, B., Khoshnia, M., Jaafari, E., Mohammadifard, N., Malekzadeh, F., Merat, S., Sadeghi, M., Naemi, M., Etemadi, A., Thomas, G. N., Sarrafzadegan, N. Tags: Original scientific paper Source Type: research

Effect of folic acid supplementation on risk of new‐onset diabetes in adults with hypertension in China: Findings from the CSPPT
ConclusionsAmong adults with hypertension with no history of stroke and/or MI in China, folic acid supplementation had no significant effect on the risk of new‐onset diabetes. This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes - October 11, 2015 Category: Endocrinology Authors: Xianhui Qin, Jianping Li, Yan Zhang, Dafang Chen, Binyan Wang, Mingli He, Jia Fu, Genfu Tang, Yefeng Cai, Xiuli Shi, Xin Xu, Fan Fan Hou, Xiaobin Wang, Yong Huo Tags: Original Article Source Type: research

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Conclusions LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths. Clinical Trial Registration https://clinicaltrials.gov/, NCT01035255.
Source: European Heart Journal - August 7, 2015 Category: Cardiology Authors: Desai, A. S., McMurray, J. J. V., Packer, M., Swedberg, K., Rouleau, J. L., Chen, F., Gong, J., Rizkala, A. R., Brahimi, A., Claggett, B., Finn, P. V., Hartley, L. H., Liu, J., Lefkowitz, M., Shi, V., Zile, M. R., Solomon, S. D. Tags: Heart failure/cardiomyopathy Source Type: research

In Context News in brief
Folic acid can reduce risk of first stroke, according to the results of a double-blind trial. 20 702 people with hypertension without a history of stroke or myocardial infarction enrolled in the China Stroke Primary Prevention Trial were randomly assigned to receive either combined enalapril 10 mg and folic acid 0·8 mg or enalapril 10 mg alone. The trial was terminated early, after a median of 4·5 years, when benefits of the combined treatment were identified: there was a significant reduction in risk of first stroke in the folic acid-enalapril group (hazard ratio 0·79, 95% CI 0·68–0·93) compared with enalapril alone group.
Source: Lancet Neurology - April 13, 2015 Category: Neurology Tags: In Context Source Type: research